FDA Approves Bayer's Low-Dose MRI Contrast Agent Ambelvist

The U.S. Food and Drug Administration (FDA) has approved Bayer's AMBELVIST® (gadoquatrane), a macrocyclic gadolinium-based contrast agent (GBCA) for use with contrast-enhanced magnetic resonance imaging (MRI) in adults and pediatric patients, including term neonates.

The agent is indicated for visualization of lesions with abnormal blood-brain barrier disruption and/or abnormal vascularity in the central nervous system, as well as for contrast-enhanced MRI of the head and neck, thorax, abdomen, pelvis, and musculoskeletal system.

According to Bayer, Ambelvist is the first and only GBCA approved in the United States at a dose of 0.04 mmol gadolinium per kilogram of body weight—approximately 60% lower than the standard 0.1 mmol/kg dose used for currently available macrocyclic GBCAs.

The FDA approval is supported by findings from Bayer's Phase III QUANTI clinical development program, which evaluated the diagnostic performance and safety of gadoquatrane in adults and children undergoing contrast-enhanced MRI. The studies demonstrated noninferior diagnostic efficacy compared with standard-dose macrocyclic contrast agents while using substantially less gadolinium.

"There is a rising need for medical imaging, among others, driven by the increasing incidence of chronic diseases such as cancer and cardiovascular diseases," said Konstanze Diefenbach, PhD, Head of Radiology Research & Development at Bayer. "With AMBELVIST, we can now provide a new low-dose GBCA option that may help reduce gadolinium exposure while maintaining diagnostic performance."

The approval comes as radiology practices continue to focus on optimizing contrast use and minimizing gadolinium exposure, particularly in patients requiring repeated MRI examinations. Although macrocyclic GBCAs are generally considered highly stable and have favorable safety profiles, interest in lower-dose contrast agents has increased in recent years.

Bayer reports that Ambelvist's high-relaxivity molecular design enables the lower gadolinium dose while preserving image enhancement and lesion visualization. The company noted that nearly 40 million MRI examinations are performed annually in the United States, many of which require contrast administration.

Ambelvist expands Bayer's MRI contrast portfolio and follows the agent's earlier approval in Japan. The company said commercial availability in the United States is expected following launch preparations.